phosphate therapeutics ltd.
phosphate therapeutics ltd. Company Information
Company Number
07618820
Next Accounts
Sep 2025
Industry
Other research and experimental development on natural sciences and engineering
Shareholders
shield therapeutics plc
Group Structure
View All
Contact
Registered Address
northern design centre, baltic business quarter, gateshead quays, tyne and wear, NE8 3DF
phosphate therapeutics ltd. Estimated Valuation
Pomanda estimates the enterprise value of PHOSPHATE THERAPEUTICS LTD. at £0 based on a Turnover of £0 and 1.24x industry multiple (adjusted for size and gross margin).
phosphate therapeutics ltd. Estimated Valuation
Pomanda estimates the enterprise value of PHOSPHATE THERAPEUTICS LTD. at £4m based on an EBITDA of £705k and a 5.71x industry multiple (adjusted for size and gross margin).
phosphate therapeutics ltd. Estimated Valuation
Pomanda estimates the enterprise value of PHOSPHATE THERAPEUTICS LTD. at £0 based on Net Assets of £-26k and 2.07x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Phosphate Therapeutics Ltd. Overview
Phosphate Therapeutics Ltd. is a live company located in gateshead quays, NE8 3DF with a Companies House number of 07618820. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in May 2011, it's largest shareholder is shield therapeutics plc with a 100% stake. Phosphate Therapeutics Ltd. is a established, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Phosphate Therapeutics Ltd. Health Check
There is insufficient data available to calculate a health check for Phosphate Therapeutics Ltd.. Company Health Check FAQs
0 Strong
0 Regular
2 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Phosphate Therapeutics Ltd.
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Phosphate Therapeutics Ltd.
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Phosphate Therapeutics Ltd.
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Phosphate Therapeutics Ltd.
- - Industry AVG
Employees
with 1 employees, this is below the industry average (44)
- Phosphate Therapeutics Ltd.
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Phosphate Therapeutics Ltd.
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Phosphate Therapeutics Ltd.
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Phosphate Therapeutics Ltd.
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Phosphate Therapeutics Ltd.
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Phosphate Therapeutics Ltd.
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Phosphate Therapeutics Ltd.
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 2700%, this is a higher level of debt than the average (44.4%)
- - Phosphate Therapeutics Ltd.
- - Industry AVG
PHOSPHATE THERAPEUTICS LTD. financials
Phosphate Therapeutics Ltd.'s latest turnover from December 2023 is 0 and the company has net assets of -£26 thousand. According to their latest financial statements, we estimate that Phosphate Therapeutics Ltd. has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Income Or Grants | 0 | ||||||||||||
| Cost Of Sales | 259,000 | ||||||||||||
| Gross Profit | -259,000 | ||||||||||||
| Admin Expenses | 457,000 | ||||||||||||
| Operating Profit | 705,000 | -708,000 | -125,000 | -62,000 | -114,000 | -112,000 | -98,000 | 255,000 | -3,281,000 | -3,017,000 | -1,753,000 | -716,000 | |
| Interest Payable | 10,000 | 11,000 | 6,000 | 5,000 | 5,000 | 0 | 4,000 | 412,000 | 2,217,000 | 1,410,000 | 767,000 | 0 | |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 4,000 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Pre-Tax Profit | 695,000 | -719,000 | -131,000 | -67,000 | -119,000 | -116,000 | -94,000 | -105,000 | -5,728,000 | -4,717,000 | -2,516,000 | -716,000 | |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20,000 | 0 | -280,000 | 286,000 | 19,000 | |
| Profit After Tax | 695,000 | -719,000 | -131,000 | -67,000 | -119,000 | -116,000 | -94,000 | -125,000 | -5,728,000 | -4,997,000 | -2,230,000 | -697,000 | |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Retained Profit | 695,000 | -719,000 | -131,000 | -67,000 | -119,000 | -116,000 | -94,000 | -125,000 | -5,728,000 | -4,997,000 | -2,230,000 | -697,000 | |
| Employee Costs | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27,000 | 35,000 | 28,000 | ||
| Number Of Employees | 3 | 4 | 2 | 3 | 3 | 3 | 3 | ||||||
| EBITDA* | 705,000 | -708,000 | -76,000 | 14,000 | -41,000 | -112,000 | -36,000 | 317,000 | -3,122,000 | -2,954,000 | -1,753,000 | -716,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 657,000 | 697,000 | 724,000 | 763,000 | 791,000 | 847,000 | 734,000 | 846,000 | 865,000 | 806,000 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 657,000 | 697,000 | 724,000 | 763,000 | 791,000 | 847,000 | 734,000 | 846,000 | 865,000 | 806,000 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 1,000 | 0 | 5,000 | 5,000 | 4,000 | 0 | 1,000 | 20,000 | 82,000 | 206,000 | 166,000 | 263,000 | 0 |
| Cash | 0 | 0 | 0 | 0 | 0 | 3,000 | 10,000 | 29,000 | 259,000 | 6,000 | 1,331,000 | 2,446,000 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1,563,000 | 306,000 | 0 | 0 |
| total current assets | 1,000 | 0 | 5,000 | 5,000 | 4,000 | 3,000 | 11,000 | 49,000 | 341,000 | 1,775,000 | 1,803,000 | 2,709,000 | 0 |
| total assets | 1,000 | 0 | 662,000 | 702,000 | 728,000 | 766,000 | 802,000 | 896,000 | 1,075,000 | 2,621,000 | 2,668,000 | 3,515,000 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 5,000 | 0 | 0 | 28,000 | 0 | 0 | 4,000 | 119,000 | 329,000 | 645,000 | 389,000 | 137,000 | 0 |
| Group/Directors Accounts | 0 | 702,000 | 651,000 | 532,000 | 517,000 | 394,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14,560,000 | 10,353,000 | 5,612,000 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 22,000 | 19,000 | 13,000 | 13,000 | 15,000 | 57,000 | 367,000 | 252,000 | 506,000 | 215,000 | 262,000 | 40,000 | 0 |
| total current liabilities | 27,000 | 721,000 | 664,000 | 573,000 | 532,000 | 451,000 | 371,000 | 371,000 | 15,395,000 | 11,213,000 | 6,263,000 | 177,000 | 0 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total liabilities | 27,000 | 721,000 | 664,000 | 573,000 | 532,000 | 451,000 | 371,000 | 371,000 | 15,395,000 | 11,213,000 | 6,263,000 | 177,000 | 0 |
| net assets | -26,000 | -721,000 | -2,000 | 129,000 | 196,000 | 315,000 | 431,000 | 525,000 | -14,320,000 | -8,592,000 | -3,595,000 | 3,338,000 | 0 |
| total shareholders funds | -26,000 | -721,000 | -2,000 | 129,000 | 196,000 | 315,000 | 431,000 | 525,000 | -14,320,000 | -8,592,000 | -3,595,000 | 3,338,000 | 0 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Operating Profit | 705,000 | -708,000 | -125,000 | -62,000 | -114,000 | -112,000 | -98,000 | 255,000 | -3,281,000 | -3,017,000 | -1,753,000 | -716,000 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Amortisation | 0 | 0 | 49,000 | 76,000 | 73,000 | 0 | 62,000 | 62,000 | 159,000 | 63,000 | 0 | ||
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -20,000 | 0 | -280,000 | 286,000 | 19,000 | |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 1,000 | -5,000 | 0 | 1,000 | 4,000 | -1,000 | -19,000 | -62,000 | -124,000 | 40,000 | -97,000 | 263,000 | 0 |
| Creditors | 5,000 | 0 | -28,000 | 28,000 | 0 | -4,000 | -115,000 | -210,000 | -316,000 | 256,000 | 252,000 | 137,000 | 0 |
| Accruals and Deferred Income | 3,000 | 6,000 | 0 | -2,000 | -42,000 | -310,000 | 115,000 | -254,000 | 291,000 | -47,000 | 222,000 | 40,000 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | 712,000 | -697,000 | -104,000 | 39,000 | -87,000 | -425,000 | -17,000 | -105,000 | -3,023,000 | -3,065,000 | -896,000 | ||
| Investing Activities | |||||||||||||
| capital expenditure | |||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||||
| Financing Activities | |||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | -702,000 | 51,000 | 119,000 | 15,000 | 123,000 | 394,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -14,560,000 | 4,207,000 | 4,741,000 | 5,612,000 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||
| interest | -10,000 | -11,000 | -6,000 | -5,000 | -5,000 | 4,000 | -4,000 | -412,000 | -2,217,000 | -1,410,000 | -767,000 | 0 | |
| cash flow from financing | -712,000 | 40,000 | 113,000 | 10,000 | 118,000 | 398,000 | -4,000 | -2,000 | 1,990,000 | 3,331,000 | 142,000 | 4,035,000 | |
| cash and cash equivalents | |||||||||||||
| cash | 0 | 0 | 0 | 0 | -3,000 | -7,000 | -19,000 | -230,000 | 253,000 | -1,325,000 | -1,115,000 | 2,446,000 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 0 | 0 | 0 | 0 | -3,000 | -7,000 | -19,000 | -230,000 | 253,000 | -1,325,000 | -1,115,000 | 2,446,000 | 0 |
phosphate therapeutics ltd. Credit Report and Business Information
Phosphate Therapeutics Ltd. Competitor Analysis
Perform a competitor analysis for phosphate therapeutics ltd. by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other established companies, companies in NE8 area or any other competitors across 12 key performance metrics.
phosphate therapeutics ltd. Ownership
PHOSPHATE THERAPEUTICS LTD. group structure
Phosphate Therapeutics Ltd. has no subsidiary companies.
phosphate therapeutics ltd. directors
Phosphate Therapeutics Ltd. currently has 2 directors. The longest serving directors include Mrs Lucy Huntington-Bailey (Apr 2020) and Mr Paul Spoors (Nov 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mrs Lucy Huntington-Bailey | 37 years | Apr 2020 | - | Director | |
| Mr Paul Spoors | United Kingdom | 43 years | Nov 2023 | - | Director |
P&L
December 2023turnover
0
0%
operating profit
705k
-200%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
-26k
-0.96%
total assets
1k
0%
cash
0
0%
net assets
Total assets minus all liabilities
phosphate therapeutics ltd. company details
company number
07618820
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
May 2011
age
14
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
FORVIS MAZARS LLP
address
northern design centre, baltic business quarter, gateshead quays, tyne and wear, NE8 3DF
Bank
-
Legal Advisor
-
phosphate therapeutics ltd. Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to phosphate therapeutics ltd..
phosphate therapeutics ltd. Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for PHOSPHATE THERAPEUTICS LTD.. This can take several minutes, an email will notify you when this has completed.
phosphate therapeutics ltd. Companies House Filings - See Documents
| date | description | view/download |
|---|
